Is fractional exhaled nitric oxide a treatable trait in chronic cough: a narrative review
Journal of Thoracic Disease · 2023-10 · 15 (10) · 5844-5855
DOI: 10.21037/jtd-23-135 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Thoracic Disease, 2023-10. Verfasst von Ji-Ho Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background and Objective: Current management of chronic cough is largely based on sequential therapeutic trials. The concept of treatable traits was first introduced for individualized treatment of chronic airway diseases; however, it has emerged as a potentially useful strategy in revising the management of chronic cough. This narrative review aimed to analyze the literature to determine if fractional exhaled nitric oxide (FeNO) is a treatable trait in chronic cough, compared to other type 2 biomarkers, and to summarize current knowledge and gaps in the clinical application.
Methods
An online electronic search was performed on PubMed, Web of Science, and Scopus of English-language literature with following keywords: cough, nitric oxide (NO), eosinophils, biomarker, and treatable trait. Relevance and eligibility of each article were assessed by one or more of the authors and a narrative review was composed. Key Content and Findings: Eosinophilic or type 2 airway inflammation is a major treatable trait in patients with chronic cough. Induced sputum tests are regarded as the gold standard for defining inflammatory phenotype, however, technically demanding and cannot be widely applied in clinical practice. FeNO, a practical biomarker, has emerged as an alternative to induced sputum analyses. Mechanistic and clinical evidence indicated that FeNO had a potential for diagnostic utility and treatment response predictability.
Conclusions
FeNO measurement may help to identify patients with chronic cough that will benefit from corticosteroid treatment. Further studies are warranted to determine the diagnostic roles of FeNO in the management of patients with chronic cough.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
- Department of Allergy and Clinical Immunology, Airway Sensation and Cough Research Laboratory, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
- Unit for Medicine and Clinical Research, Pulmonary Division, Kuopio University Hospital, Kuopio, Finland.
- School of Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Zitieren
APA
Lee, J. H., Lee, J. H., Park, S. Y., Koskela, H. O., & Song, W. J. (2023). Is fractional exhaled nitric oxide a treatable trait in chronic cough: a narrative review. Journal of Thoracic Disease, 15(10), 5844-5855. https://doi.org/10.21037/jtd-23-135
Vancouver
Lee JH, Lee JH, Park SY, Koskela HO, Song WJ. Is fractional exhaled nitric oxide a treatable trait in chronic cough: a narrative review. Journal of Thoracic Disease. 2023;15(10):5844-5855. doi:10.21037/jtd-23-135
BibTeX
@article{Lee2023,
author = {Lee, Ji-Ho and Lee, Ji-Hyang and Park, So-Young and Koskela, Heikki Olavi and Song, Woo-Jung},
title = {Is fractional exhaled nitric oxide a treatable trait in chronic cough: a narrative review},
journal = {Journal of Thoracic Disease},
year = {2023},
volume = {15},
number = {10},
pages = {5844--5855},
doi = {10.21037/jtd-23-135}
}
EUVIMED